Amgen asks SCOTUS to reject Roche petition

Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amgen v Sanofi: Big Pharma awaits SCOTUS decision

15 December 2022 As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Big Pharma

Roche and Bluebird settle ‘Spark’ TM suit

19 May 2022 Roche subsidiary Spark Therapeutics has settled a lawsuit with rival gene-therapy company Bluebird Bio, which it had accused of infringing its “Spark” trademarks when marketing treatment for sickle-cell disease.

More on this story

Americas

Amgen v Sanofi: Big Pharma awaits SCOTUS decision

15 December 2022 As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Big Pharma

Roche and Bluebird settle ‘Spark’ TM suit

More on this story

Americas

Amgen v Sanofi: Big Pharma awaits SCOTUS decision

15 December 2022 As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Big Pharma

Roche and Bluebird settle ‘Spark’ TM suit